Kennondale Capital Management LLC Takes Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Kennondale Capital Management LLC bought a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the fourth quarter, HoldingsChannel.com reports. The firm bought 151,280 shares of the biotechnology company’s stock, valued at approximately $755,000.

A number of other institutional investors also recently modified their holdings of the business. State Street Corp boosted its position in shares of Aldeyra Therapeutics by 1.7% in the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after acquiring an additional 16,188 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Aldeyra Therapeutics in the fourth quarter valued at about $3,628,000. Jacobs Levy Equity Management Inc. boosted its position in shares of Aldeyra Therapeutics by 163.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after acquiring an additional 295,864 shares during the period. Woodstock Corp boosted its position in shares of Aldeyra Therapeutics by 7.8% in the fourth quarter. Woodstock Corp now owns 194,919 shares of the biotechnology company’s stock valued at $973,000 after acquiring an additional 14,113 shares during the period. Finally, Barclays PLC boosted its position in shares of Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after acquiring an additional 48,313 shares during the period. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Trading Down 8.7 %

ALDX opened at $6.31 on Tuesday. Aldeyra Therapeutics, Inc has a twelve month low of $2.75 and a twelve month high of $7.20. The company has a 50-day simple moving average of $5.81 and a 200 day simple moving average of $5.48. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.30). On average, research analysts predict that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, March 3rd.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.